A novel approach to hepatits B non-responders.

Abstract

Hepatitis B is a major global pandemic affecting over 296 million people, with significant chronic disease burden. In Australia, an estimated 225,000 people live with chronic hepatitis B, with many unaware of their status.​ Hepatitis B vaccination is highly effective; however, 5–15% of individuals fail to achieve seroconversion following a complete vaccine series. Non-response is more common among older adults, males, and immunocompromised individuals. Immunocompromised populations are not only at increased risk of acquiring HBV but also tend to have reduced vaccine efficacy. ​ Non-Responder is defined as a failure to develop protective anti-HBs after two complete series, 4 – 8 weeks after last dose. Anti-HBs titre <10 mIU/mL. Traditional Non-Responder Vaccine Schedules include: A single booster dose; repeat full 3-dose series; double dose full course; intradermal course with anti-HBs serology 4- 8 weeks following schedule. Project Aim; To evaluate the effectiveness of using a 2 dose Twinrix vaccine (Hepatitis A+B) to boost Hepatitis B response, leveraging Hepatitis A as an adjuvant to enhance immunogenicity. The projects initial aim is 100 immunocompromised patients.